LIAN News and Press, LianBio From 12/03/23

2023-12-03 04:30:00 ET Summary LianBio, a Princeton-Shanghai in-licensing company, received a $465 million buyout offer from Tang Capital Management. Perpetual Medicines, a Shanghai-Boston AI startup, closed an $8 million seed financing to advance its peptide drug discovery platfo...

2023-12-01 17:20:57 ET More on LianBio LianBio receives buyout offer of $4.30 per share, plus CVR Top 10 stocks under $10, as ranked by SA's Quant Ratings Seeking Alpha’s Quant Rating on LianBio Historical earnings data for LianBio Financial in...

SHANGHAI, China and PRINCETON, N.J., Dec. 01, 2023 (GLOBE NEWSWIRE) -- The Board of Directors (the “Board”) of LianBio (NASDAQ: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today confirmed that Concentr...

2023-12-01 15:07:05 ET More on LianBio Top 10 stocks under $10, as ranked by SA's Quant Ratings LianBio shares soar after agreement with Bristol Myers Squibb Seeking Alpha’s Quant Rating on LianBio Historical earnings data for LianBio Financial...

2023-11-15 11:44:02 ET More on Markets UBS highlights 14 stocks on its list of high-conviction names Global X says AI, cybersecurity among four key themes for 2024 Cathie Wood's ARK Invest launches crypto ETFs in partnership with 21Shares Producer Price Index...

2023-11-14 02:09:11 ET More on LianBio LianBio shares soar after agreement with Bristol Myers Squibb Seeking Alpha’s Quant Rating on LianBio Historical earnings data for LianBio Financial information for LianBio For further details see: Lia...

Entered into agreement with Bristol Myers Squibb for mavacamten in China and other Asian markets Phase 3 data from EXPLORER-CN trial of mavacamten presented in an oral late-breaking science session at the European Society of Cardiology Congress 2023 with simultaneous publication in ...

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...

LianBio (LIAN) is expected to report $-0.28 for Q3 2023

SHANGHAI, China and PRINCETON, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced topline results from the Phase 3 LIBRA clinical trial evaluating TP...